Navigation Links
NIH funds development of new broad-spectrum therapeutics
Date:10/13/2011

Four companies are to develop broad-spectrum therapeuticsantibiotics, antivirals and an antitoxinto prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Total funding for the four contracts could reach $150 million over a maximum five-year period.

The contracts are designed to support essential research and development activities to enable promising investigational therapies to move toward early-phase clinical studies and, if successful in clinical studies, on to eventual licensure. The ultimate goal is to develop products that the U.S. government can stockpile to protect the public in the event of a bioterror attack or public health crisis.

In line with NIAID's strategic plan for biodefense and emerging infectious diseases research, these contracts move beyond the paradigm of drug development that is sometimes called "one-bug, one-drug." (http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Documents/biosp2007.pdf)The contracts are to focus on candidate therapies that can be used against classes of pathogens rather than being agent-specific. Such broad-spectrum therapeutics would improve preparedness for all infectious threats, whether they occur naturally or are deliberately introduced.

The following companies are recipients of the new contracts:

CUBRC Inc., Buffalo, N.Y., in partnership with Tetraphase Pharmaceuticals, Watertown, Mass.Researchers will develop a fully synthetic tetracycline product, TP-271, to treat the bacterial disease tularemia, and respiratory infections such as community-acquired bacterial pneumonia. Both intravenous and oral formulations of the drug will be evaluated in preclinical studies for safety and efficacy, and several preliminary 1 clinical trials are planned. The compound will also be tested in nonclinical studies for activity against anthrax and plague. The initial award is for $5.7 million, with the potential for up to $35 million over five years.

Enanta Pharmaceuticals Inc., Watertown, Mass.Researchers will develop and evaluate a candidate from a novel class of next-generation broad-spectrum antibiotics known as bicyclolides. Bicyclolides are small-molecule anti-infectives. Enanta's bicyclolide has demonstrated potential for activity against anthrax, plague and tularemia in cell culture studies, as well as efficacy against anthrax and tularemia in mice. The compound will be evaluated for effectiveness against multiple bacteria that might be used as agents of bioterror, and several Phase 1 clinical trials are planned. Bicyclolides represent a promising new class of broad-spectrum antibiotics that have demonstrated activity against the two major groups of bacteria, known as gram-negative and gram-positive bacteria. These groups of bacteria are distinguished by the presence or absence of peptidoglycan, which is visible in lab specimens when the bacteria are stained using the Gram method. In general, the two types of bacteria are treated using different types of drugs.The initial award is for $14.3 million with the potential for a five-year total of up to $43 million.

Unither Virology LLC, Silver Spring, Md.Unither will develop and evaluate UV-4, an investigational antiviral drug with potential as a treatment for influenza and dengue fever and possible applications for viral hemorrhagic fever, smallpox and hepatitis. The drug is derived from a class of compounds known as iminosugars that includes drugs approved for other indications, such as diabetes and Gaucher's disease. UV-4, which may also reduce the potential for drug resistance, is expected to undergo toxicity studies, a preliminary safety study and a Phase 2 clinical trial for dengue fever. Unither has received an initial award of $10.5 million with the potential for up to $45 million over five years.

XOMA (US) LLC, Berkeley, Calif.The company will develop an intravenous antitoxin to treat human botulism poisoning. XOMA's monoclonal antibody product will target serotypes C and D of Clostridium botulinum neurotoxin and would also neutralize C/D and D/c mosaic/hybrid toxins. The development of human botulinum monoclonal antibodies would replace existing horse-based antitoxin products that are difficult to make and pose safety concerns for humans. A preliminary clinical trial is planned for XOMA's anti-C/D toxin product. The company received $7 million in its initial NIAID award with the potential for up to $28 million in five years.


'/>"/>

Contact: Ann Mosher
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Federal Recovery Funds Allow Eries Shriners Hospital to Reduce Energy Costs, Invest Savings in Patient Care
2. Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds
3. Study: Federal funds support health depts., but leadership is key
4. Legacy(SM) Case for Tobacco Funds to be Heard by Ohio Supreme Court
5. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
6. EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
7. Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds
8. Prize4Life Launches “Art, Life, Spring” Online Art Auction to Raise Funds for Lou Gehrig's Disease Research
9. Just Graduated College Seniors Ride for Loved Ones With Diabetes Cycling Cross Country to Raise Funds to Help Find a Cure
10. Only 5 percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients
11. Amazing Grace Charity Golf Tournament to Raise Awareness, Funds for Neuroblastoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets ... report to their offering. ... The global chromatography market to grow ... Global Chromatography Market 2016-2020, has been prepared based on an in-depth market ... and its growth prospects over the coming years. The report also includes ...
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
(Date:12/8/2016)... 8, 2016  Agenovir Corporation, a company using ... therapeutics, today announced that it appointed Dirk ... a member of the board of directors. ... a deep background in both founding and building ... Agenovir, co-president of Chan Zuckerberg  Biohub and ...
Breaking Medicine Technology: